title: Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.
abstract: In the present study, the possible interactions between celecoxib and some excipients (colloidal silicon dioxide (Aerosil), microcrystalline cellulose (Avicel PH 102), lactose anhydrous, magnesium stearate, cross-povidone and talc) were evaluated by examining the pure drug or drug-excipient powder mixtures which were stored under different conditions (25 +/- 2 degrees C, 60% RH +/- 5% RH or 40 + 2 degrees C, 75% RH +/- 5% RH) and different period (30 or 60 days) using DSC, FT-IR and HPLC. In order to investigate the possibility of celecoxib-excipient interaction in aqueous medium, dispersions of the pure drug or drug in physical powder mixture (1:1 w/w) in water (1%, w/v) were also prepared and evaluated by FT-IR and HPLC at day 0 and day 7 (40 +/- 2 degrees C). The interaction between celecoxib and magnesium stearate or colloidal silicon dioxide were determined in the aqueous dispersions by FT-IR. Different tablet formulations with or without excipients tested were prepared, and assessed for drug dissolution and permeability.
authors.affiliation: Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
authors.forename: Sibel
authors.initials: S
authors.lastname: Bozdağ-Pehlivan
authors.forename: Birsel
authors.initials: B
authors.lastname: Subaşi
authors.forename: Imran
authors.initials: I
authors.lastname: Vural
authors.forename: Nurşen
authors.initials: N
authors.lastname: Unlü
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Capan
mesh_terms: D018938:Caco-2 Cells; D002152:Calorimetry, Differential Scanning; D000068579:Celecoxib; D002482:Cellulose / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D052246:Cyclooxygenase 2 Inhibitors / Q000737:chemistry* / Q000378:metabolism; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D006801:Humans; D006813:Humidity; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007785:Lactose / Q000737:chemistry; D010539:Permeability; D011205:Povidone / Q000737:chemistry; D011720:Pyrazoles / Q000737:chemistry* / Q000378:metabolism; D012822:Silicon Dioxide / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013229:Stearic Acids / Q000737:chemistry; D013449:Sulfonamides / Q000737:chemistry* / Q000378:metabolism; D013607:Tablets; D013627:Talc / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods; D013696:Temperature; D013997:Time Factors
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D005079:Excipients; D011720:Pyrazoles; D013229:Stearic Acids; D013449:Sulfonamides; D013607:Tablets; D013627:Talc; C031183:stearic acid; D012822:Silicon Dioxide; D002482:Cellulose; D011205:Povidone; D007785:Lactose; D000068579:Celecoxib; C109691:microcrystalline cellulose